Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Hallam University, Sheffield, UK.
Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
Eur Urol. 2015 Jan;67(1):114-122. doi: 10.1016/j.eururo.2014.08.072. Epub 2014 Oct 7.
The international prostate symptom score (IPSS) evaluates lower urinary tract symptoms (LUTS) in men with suspected benign prostatic hyperplasia (BPH); the total score does not differentiate between storage and voiding and is unevenly weighted (four questions [57%] on voiding, three questions [43%] on storage).
To evaluate the relative contributions of storage and voiding IPSS subscores to total IPSS at baseline and in response to treatment with tadalafil.
DESIGN, SETTING, AND PARTICIPANTS: Integrated analysis of data from four placebo-controlled, 12-wk studies of tadalafil (5mg once daily) in 1499 men with LUTS/BPH.
Relationships between total IPSS and the storage and voiding subscores were assessed using graphical exploration and linear regression modelling. Linear modelling was performed for the baseline and endpoint and for changes in subscores. The optimal storage subscore to total IPSS (S:T) ratio for IPSS improvement was identified using nonparametric regression and gradient-descent optimisation.
The contribution of storage and voiding subscores at baseline and endpoint was 38.8% and 61.2%, and 39.2% and 60.7%, respectively. This intuitive 40:60 storage-to-voiding ratio was similar at baseline and endpoint by treatment group and for changes in subscores, but spanned the entire range for individuals. Changes in total IPSS were greatest for a storage subscore percentage contribution to total IPSS of 42.7%. There was no statistical association between S:T ratio (≥ 40% vs < 40%) at baseline and response to tadalafil. The main limitation was the use of unvalidated storage and voiding IPSS subscores.
A constant S:T ratio of 4:10 was observed at baseline and endpoint. The greatest effect on total IPSS was noted for an S:T percentage contribution of 42.7%. Tadalafil efficacy was unaffected by the level of storage dysfunction at baseline.
This analysis shows that for men with BPH, improvements during treatment with tadalafil apply to both storage and voiding symptoms at a constant ratio. The extent of storage dysfunction before treatment did not affect the response to treatment.
国际前列腺症状评分(IPSS)评估疑似良性前列腺增生(BPH)男性的下尿路症状(LUTS);总评分不能区分存储和排空,且权重不均(排空 4 个问题[57%],存储 3 个问题[43%])。
评估存储和排空 IPSS 子评分对基线和他达拉非治疗反应时总 IPSS 的相对贡献。
设计、地点和参与者:对四项安慰剂对照、12 周他达拉非(5mg 每日一次)治疗 1499 例 LUTS/BPH 男性的研究数据进行综合分析。
使用图形探索和线性回归模型评估总 IPSS 与存储和排空子评分之间的关系。对基线和终点以及子评分变化进行线性建模。使用非参数回归和梯度下降优化确定 IPSS 改善的最佳存储子评分与总 IPSS(S:T)比值。
基线和终点时存储和排空子评分的贡献分别为 38.8%和 61.2%,39.2%和 60.7%。这种直观的 40:60 存储与排空比值在治疗组和子评分变化时在基线和终点时相似,但个体差异很大。总 IPSS 的变化最大,存储子评分对总 IPSS 的贡献百分比为 42.7%。基线时 S:T 比值(≥40%与<40%)与他达拉非的反应之间无统计学关联。主要限制是使用未经验证的存储和排空 IPSS 子评分。
在基线和终点时观察到恒定的 S:T 比值为 4:10。总 IPSS 的最大影响发生在 S:T 百分比贡献为 42.7%时。治疗前储存功能障碍的程度不影响治疗的反应。
该分析表明,对于 BPH 男性,他达拉非治疗期间的改善适用于存储和排空症状,且比例恒定。治疗前储存功能障碍的程度不影响治疗反应。